Sellas Life Sciences Group (SLS) said Thursday it has dosed the first pediatric patient in the ongoing phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia.
The study will assess the safety, tolerability and efficacy of SLS009 in combination with venetoclax and azacitidine at doses of 45 and 60 mg, the company said.
The company said it received the Rare Pediatric Disease Designation for the program from the Food and Drug Administration for the treatment of pediatric acute myeloid leukemia last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.